EMA recommends approval of BioMarin production plant
The two Novato facilities are said to support up to $1bn in revenue for BioMarin’s growing enzyme replacement therapy portfolio. BioMarin CEO Jean-Jacques Bienaime said the company is
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.